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Abstract
High mobility group box 1 (HMGB1) is named for its electrophoretic mobility on pol‐
yacrylamide gels when it was first identified in calf thymus in 1973. HMGB1 plays a
critical role in the stress response not only inside the cell as a DNA chaperone and cell
death regulator, but also outside the cell as the prototypic damage-associated molecu‐
lar pattern molecule. The physiological and pathological role of HMGB1 in health and
disease has been widely studied for years. In this chapter, we will focus on the release
and function of HMGB1 in cell death types such as apoptosis, autophagy, and ne‐
crosis.
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1. Introduction
Cell death is the cell’s process of losing its biological ability to carry out all the essential life
processes. The Nomenclature Committee on Cell Death proposes several cell death classifica‐
tion criteria. According to morphological appearance, cell death is divided into apoptosis (type
I), autophagy (type II), and necrosis (type III) [1, 2]. According to enzymological qualities, cell
death is divided into several subtypes depending on the involvement or noninvolvement of
nuclei or distinct protease classes such as caspases, calpains, cathepsins, and transglutami‐
nases. According to immunological characteristics, cell death is divided into immunogenic or
tolerogenic cell death [3]. For example, apoptosis is generally considered nonimmunogenic
cell death, whereas necrosis is considered immunogenic cell death. In addition, cell death can
be classified into regulated or accidental cell death based on functional aspects [4]. Accidental
cell death is caused by unexpected and accidental cell damage (e.g., ischemic and trauma),
whereas regulated cell death is mediated by an expected program in response to different
stimuli. The list of regulated cell death subtypes is rapidly increasing and includes anoikis,
autophagic cell death, apoptosis, cornification, entosis, ferroptosis, mitotic catastrophe,
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necroptosis, netosis, parthanatos, and pyroptosis [4]. Cell death is essential for a plethora of
physiological processes, and its deregulation is implicated in several human diseases such as
infections, neurodegeneration, cancer, autoimmunity, and ischemic disease [5-7]. During the
past few decades, a number of important concepts regarding the regulation of cell death and
its roles in human health and disease have arisen. Understanding the molecular mechanisms
and signaling pathways of cell death is crucial for identifying new diagnostic and therapeutic
targets.
Compared to pathogen-associated molecular pattern molecules (PAMPs), which are generated
from the components of foreign pathogens such as bacteria and viruses, damage-associated
molecular pattern molecules (DAMPs) are endogenous or self-molecules that are secreted,
released, or undergo surface exposure by dead, dying, or injured cells [8-12]. Both PAMPs and
DAMPs are mainly recognized by pattern recognition receptors such as receptor for advanced
glycation end products (RAGE) and toll-like receptors (TLRs) to mediate the inflammatory,
immunity, and metabolism response. The release and activity of DAMPs during cell death can
determine whether cell death is immunogenic or tolerogenic [13]. Thus, DAMPs are suitable
emergent targets for cell-death-associated immune therapy.
High mobility group box 1 (HMGB1) is named for its electrophoretic mobility on polyacryla‐
mide gels when it was first identified in calf thymus in 1973 [14]. As an extremely conserved
protein, HMGB1 originated before the divergence of the protostomes and deuterostomes,
approximately 525 million years ago [15]. HMGB1 shares 100% amino acid sequence identity
between mice and rats, and a 99% homology between rodents and humans [16-18]. The
homolog of mammalian HMGB1 has been reported for several species such as Nhp6A/B in
yeast and HMG-D and DSP1 in Drosophila [19-21]. HMGB1 plays a critical role in the stress
response not only inside the cell as a DNA chaperone and cell death regulator, but also outside
the cell as the prototypic DAMP. The physiological and pathological role of HMGB1 in health
and disease has been widely studied for years [22]. In this chapter, we will focus on the release
and function of HMGB1 in cell death types such as apoptosis, autophagy, and necrosis.
2. HMGB1 structure and function
2.1. Structure
Human HMGB1 consists of 215 amino acid residues and has two L-shaped DNA-binding
domains (HMG A box [9-79aa], HMG B box [95-163aa]) and a shorter C-terminal tail
(186-215aa) [23]. Both A- and B-box domains are necessary for efficient DNA bending and
flexure. HMGB1 binds to DNA without apparent sequence specificity. HMGB1 normally
locates in the nucleus due to two nuclear-localization signals (NLS): NLS1 (28-44aa) and NLS2
(179-185aa) [24]. In contrast, HMGB1 contains nuclear-emigration signals in DNA-binding
domains, which contributes to extranuclear HMGB1 during stress in a nuclear exportin
chromosome-region maintenance 1-dependent manner. In addition to DNA, HMGB1 can bind
a number of proteins involved in multiple biologic processes. For example, HMGB1 binds to
RAGE, TLR4, and p53 by residues 150-183, 89-108, and 7-74, which mediates cell migration
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[25], cytokine production [26], and gene transcription [27], respectively. The recombinant B
box protein exhibits proinflammatory activity, whereas the recombinant A box protein
displays anti-inflammatory activity [28], although the potential mechanism remains unknown.
The C terminus is composed of 30 acidic amino acid residues and is able to regulate DNA
binding/bending by intramolecular interaction with the A- and B- box [29, 30] or by intermo‐
lecular interaction with histones (e.g., H1 and H3) [31, 32]. Additionally, residues 201-205 in
the C-terminal acidic tail region contribute to the antibacterial activity of recombinant HMGB1
[33]. Hence, the structural basis of HMGB1 determines its biological function.
2.2. Intracellular HMGB1
2.2.1. Nuclear HMGB1
HMGB1 translocates  between the cytoplasm and the nucleus,  but  normally  stays  in  the
nucleus in most cells and tissues. Nuclear HMGB1 is the structural protein of chromatin and
orchestrates  a  number  of  nuclear  events  by  its  DNA  chaperone  activity  as  follows:  (1)
Nucleosome stability and sliding. As basic unit of chromatin, nucleosome contains a short
length of DNA wrapped around a core of histone proteins. HMGB1 and histone H1 can bind
to linker DNA between successive nucleosomes in the chromatin fiber [34]. H1 stabilizes
nucleosome with less mobility, whereas HMGB1 relaxes nucleosome and makes chromatin
more accessible at the distorted site [35, 36]. (2) Nucleosome number and genome chromati‐
nization. Loss of HMGB1 in mammalian and yeast cells leads to 20-30% less histones and
nucleosomes and more RNA transcripts [37]. (3) Nuclear catastrophe and nucleosome release.
Conditional  knockout  of  HMGB1  in  the  pancreas  causes  nuclear  oxidative  injury  and
proinflammatory nucleosome release, which mediates sterile inflammation [38].  (4) DNA
bending and binding. HMGB1 binds to DNA with structure-specificity, but not sequence-
specificity [39]. After binding DNA, the major function of HMGB1 is to bend and change
DNA conformation by unwinding [40], looping [41], or compacting DNA [42]. This DNA
chaperone activity of HMGB1 is implicated in the regulation of gene transcription [43], DNA
repair [44], DNA replication [45], V(D)J recombination [46], gene delivery [47], and gene
transfer [48]. (5) Telomere homeostasis. Loss of HMGB1 in yeast and mammalian cells inhibits
telomerase activity, decreases telomere length, and increases DNA damage and chromoso‐
mal instability [49].
2.2.2. Cytosolic HMGB1
Several cell types (e.g., fibroblasts [50], thymocytes [51]), and tissue types (e.g., liver, kidney,
heart, and lung) [52] have normal cytosolic HMGB1 expression. The ratio of nuclear to
cytoplasmic HMGB1 is about 30:1 [52]. Importantly, the translation of HMGB1 from the
nucleus to the cytosol, including mitochondria and lysosomes, are observed in response to
various stressors (e.g., cytokines, chemokines, heat, hypoxia, oxidative stress, and oncogenes).
Although the function of cytosolic HMGB1 still remains poorly studied, HMGB1 may act as a
positive regulator of mitochondrial quality in an autophagy-dependent and autophagy-
independent manner [53, 54], which will be discussed later in the “Autophagy” section. In
addition to autophagy, cytosolic HMGB1 is involved in the regulation of unconventional
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secretory pathways based on mass spectrometry-mediated binding partner analysis [55]. In
one study, several HMGB1-binding partners in nuclear and cytosol fraction were identified in
several cancer cells [55]. Among them, nine of the cytosolic HMGB1-binding proteins were
related to protein translocation and secretion. In particular, immunoprecipitation analysis
further confirmed four cytosolic HMGB1-binding proteins, including annexin A2, myosin IC
isoform a, myosin-9, and Ras-related protein Rab10 [55]. These proteins are directly implicated
in the process of unconventional protein secretion. Further studies are needed to define the
function of cytosolic HMGB1 in unconventional protein secretion. In addition to nuclear and
cytosolic HMGB1, intracellular HMGB1 presents on cell surface membranes and regulates
neurite outgrowth [56], platelet activation [57, 58], cell differentiation [59], erythroid matura‐
tion [60], adhesion [61], and innate immunity [62].
2.3. Extracellular HMGB1
HMGB1 is released in two different ways. On the one hand, HMGB1 can be actively secreted
by normal cells, especially immune and endothelial cells [63, 64]. On the other hand, HMGB1
can be passively released by dead, dying, or injured cells in response to autophagic cell death
[65], apoptosis [66, 67], necrosis [68], necroptosis [69, 70], netosis [71], and pyroptosis [72].
Oxidative stress refers to elevated intracellular levels of reactive oxygen species (ROS) that
play a central role in the regulation of HMGB1 secretion and release, although the actual
mechanism of action remains ambiguous [73]. Once released, HMGB1 acts as a cytokine,
chemokine, and growth factor that is implicated in multiple biological processes including
inflammation, immunity, migration, invasion, metabolism, proliferation, differentiation,
antimicrobial defense, angiogenesis, tissue regeneration, death, autophagy, senescence, and
efferocytosis. Extracellular HMGB1 plays important roles in the pathogenesis of human
disease and is a potential therapy target in infection and sterile inflammation [74-76]. Several
factors can affect HMGB1 activity in different experimental settings. For example, RAGE [77]
and TLRs [78, 79] are positive receptors in macrophages and fibroblasts, whereas CD24 [80]
and T cell immunoglobulin mucin 3 [81, 82] are negative receptors of HMGB1-mediated
signaling in macrophages and dendritic cells (DCs). In addition to receptors, HMGB1 can be
directly taken up and mediate the inflammatory and metabolism response [83, 84]. Ultra-pure
HMGB1 (free from contaminating bacterial proteins and nucleic acids) exhibits very low
immune activity in macrophages. In contrast, extracellular HMGB1 is in fact a “sticky” protein
and a synergistic immune effect is observed between HMGB1 and PAMPs (e.g., lipopolysac‐
charide), DAMPs (e.g., DNA), and other molecules (e.g., cytokines, chemokine, and IgG) in
multiple cells [85]. Thus, serum and plasma components (e.g., immunoglobulins, phospholi‐
pids, thrombomodulin, and proteoglycans) can interfere with HMGB1 detection by enzyme-
linked immunosorbent assay [86]. Another important factor affecting HMGB1 activity is its
redox status [87]. HMGB1 contains three conserved redox-sensitive cysteine residues: C23,
C45, and C106. Reduced all-thiol-HMGB1 only exhibits chemokine activity, whereas disulfide-
HMGB1 displays only cytokine activity, and oxidized HMGB1 has neither in immune cells
[88]. In addition, reduced HMGB1 induces autophagy, whereas oxidized HMGB1 triggers
apoptosis in cancer cells [89]. This redox status of HMGB1 also affects the affinity between
HMGB1 and its receptors [26]. A recent study demonstrates that HMGB1 is specifically cleaved
Cell Death - Autophagy, Apoptosis and Necrosis400
by caspase-1 but not other caspases during inflammasome activation [90]. Collectively, the
release and activity of HMGB1 is context-dependent.
3. HMGB1 regulates cell death
3.1. Mechanism of HMGB1-mediated autophagy regulation
Autophagy, including macroautophagy, microautophagy, and chaperone-mediated autoph‐
agy, is a highly conserved degradation process in organisms from yeasts to plants and animals
[91]. The well-studied form of autophagy is macroautophagy (hereafter referred to as autoph‐
agy). As a complex dynamic process, autophagy is composed of the formation and maturation
of three major membrane structures: the phagophore, autophagosome, and autolysosome [92].
Briefly, the phagophore originates from multiple membrane resources and engulfs the
cytosolic materials, which leads to the formation of a closed autophagosome with a double
membrane. Of note, microtubule-associated protein light chain 3 (LC3)-II is a widely used
autophagosome marker [93]. Finally, autophagosomes fuse with lysosomes to form autolyso‐
somes, which results in degradation of the engulfed material, including LC3-II, by lysosomal
enzymes into elementary pieces that can be used for protein synthesis and energy production.
Thus, autophagy is a programmed cell survival pathway in response to intracellular and
extracellular stress [94]. However, excessive or impaired autophagy can cause cell death,
indicating a dual role of autophagy in cell survival and cell death. In particular, autosis is an
Na+, K+-ATPase-dependent form of cell death triggered by autophagy-inducing peptides,
starvation, and hypoxia–ischemia [95]. The process of autophagy is controlled by multiple
posttranslational modifications of the autophagy-related gene (Atg) family and shares
regulators derived from other cell death pathways [96].
HMGB1 promotes autophagy in a location- and modification-dependent manner. Nuclear
HMGB1 regulates heat shock protein β-1 (HSPB1) expression at a transactional level [54]. The
protein expression of HSPB1, but not other heat shock proteins, is significantly inhibited in
HMGB1 knockout or knockdown cells.  Both HMGB1 and HSPB1 regulate mitochondrial
selective  autophagy,  namely  mitophagy,  following mitochondrial  injury  [54].  Like  other
ATGs, it was recently suggested that HMGB1-independent autophagy exists in the regula‐
tion  of  mitochondrial  quality,  including  the  mitochondrial  DNA damage  response  [53].
Cytosolic HMGB1 is a Beclin-1 binding protein [97]. HMGB1 C23S and C45S mutants lose
their ability to bind Beclin-1 and therefore cannot promote autophagy [97]. The binding of
HMGB1 with Beclin-1 is positively regulated by unc-51-like kinase 1 [98] mitogen-activated
kinase-like protein [99],  and nucleus accumbens-1 [100].  In contrast,  p53 [101],  SNCA/α-
synuclein [102], lysosomal thiol reductase [103], miR34A [104], and miR22 [105] negatively
regulate HMGB1-mediated autophagy by disrupting HMGB1-Beclin-1 complex formation.
Moreover,  activation of  poly  [ADP-ribose]  polymerase  1  (PARP1)  is  required for  tumor
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced ADP-ribosylation
of  HMGB1  and  subsequent  HMGB1-Beclin-1  complex  formation  in  cancer  cells  [106].
Extracellular reduced HMGB1, but not oxidized HMGB1, significantly induced autophagy
in cancer cells in a RAGE-dependent manner [89]. This process may sustain anaerobic energy
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production during tumor growth and development [107]. Collectively, these findings suggest
an HMGB1-dependent autophagic pathway at multiple levels in response to stress. Howev‐
er, HMGB1-independent autophagy may exist in several organs, although the underlying
mechanism of its action remains obscure [108].
3.2. Mechanism of HMGB1-mediated apoptosis regulation
Apoptosis is the process of programmed cell death and includes classical “extrinsic” and
“intrinsic” pathways and nonclassical T and natural killer cell-mediated cytolytic pathways.
The extrinsic pathway is primarily mediated by the binding of a ligand to a transmembrane
death receptor (DR). DRs are members of the TNF receptor gene superfamily, including FasR,
TNFR1, lymphotoxin receptor, DR3, and DR4/DR5 [109]. In addition to DRs, dependence
receptors mediate apoptosis by monitoring the absence of certain trophic factors or the
presence of anti-trophic factors [110]. The intrinsic pathway for apoptosis involves activation
of a mitochondrial pathway including altering mitochondrial permeability and subsequent
release of mitochondrial proteins such as cytochrome c and second mitochondrial-derived
activator of caspases [111]. The process of apoptosis is tightly regulated by the Bcl-2, caspase,
and nuclease families [112-114]. Caspases are a family of endoproteases linking inflammation
and cell death. Initiator caspases (e.g., caspases-8 and -9) activate executioner caspases (e.g.,
caspases-3, -6, and -7) that mediate the cleavage of key structural proteins such as PARP1.
However, caspase-independent apoptosis may exist by translocation of apoptosis-inducing
factor [115, 116] and endonuclease G [117] from the mitochondria to the nucleus, or activation
of Omi/HTRA2 (a mitochondrial serine protease) [118]. Remarkably, several caspases (e.g.,
caspase-1, -4, -5, and -12 in humans; caspase-1, -11, and -12 in mice) are critical mediators of
innate immune responses partly by activation of inflammasome, but not activation of the
apoptosis pathway.
Intracellular HMGB1 is generally an anti-apoptotic protein in response to several apoptotic
stimuli such as ultraviolet radiation, CD95, TRAIL, caspase-8, and Bax [119]. Knockdown of
HMGB1 increases drug sensitivity in cancer cells [120]. Mechanically, HMGB1 plays tran‐
scriptional-dependent (e.g., regulation of Bcl-2 family protein expression) and transcriptional-
independent roles (e.g., regulation of autophagy and p53 location) in the regulation of
apoptosis. For example, inhibition of HMGB1-mediated autophagy can increase caspase
activity [121]. In addition to caspases, several non-caspase proteases such as calpain (Ca2+-
dependent proteases) may play a role in the execution of apoptosis. Interestingly, HMGB1
deletion can enhance calpain activity and trigger cleavage of Beclin-1 and ATG5 [122]. Thus,
HMGB1 is an important regulator of the cross talk between apoptosis and autophagy. In
vivo, conditional knockout of HMGB1 in pancreas, liver, intestinal epithelial and myeloid cells
enhances sterile inflammation and infection partly through inhibition of autophagy and
induction of apoptosis [38, 122-124]. In some cases, overexpression of HMGB1 renders cells
sensitive to apoptosis in response to chemotherapy agents [125]. In addition, extracellular
oxidized HMGB1 can induce caspase-dependent apoptosis in cancer cells [89]. These findings
suggest that HMGB1 plays dual roles in the regulation of apoptosis.
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3.3. Mechanism of HMGB1-mediated necrosis regulation
Necrosis includes accidental and regulated necrosis [2]. Partially, the term “necroptosis” has
recently been used to describe regulated necrosis when cells lack the capacity to activate
caspase [126]. Necroptosis is mediated by a signaling complex called necrosome, containing
receptor-interacting protein (RIP)1, RIP3, and mixed-lineage kinase domain-like (MLKL) [127,
128], and can be inhibited by small molecule inhibitors necrostatin 1 and necrosulfonamide
[129, 130] [126]. The fundamental causes of necrosis include calcium overload, ROS generation,
cellular energy depletion, and membrane lipid injury [131]. PARP is a protein family involved
in a number of cellular processes such as DNA repair and programmed cell death. Induced
overactivation of PARP1 can lead to adenosine triphosphate (ATP) depletion and subsequent
necrosis [132]. The process of necrosis ends with the leaking out of enzymes from lysosomes
to digest cell components that are associated with HMGB1 release. In vivo, loss of HMGB1 in
the pancreas increases L-arginine-induced apoptosis and necrosis due to oxidative injury [38].
However, the role of HMGB1 in necroptosis remains undefined.
4. HMGB1 release in cell death
4.1. Mechanism of HMGB1 release in autophagy
Autophagic cell death is not only a morphologic notion such as cell death associated with
autophagosomes and autolysosomes, but also a functional description that excessive autoph‐
agy can cause cell death. Induction of autophagy facilitates both active secretion and passive
release of HMGB1. For example, the release of HMGB1 is significantly increased in response
to epidermal growth factor (EGF) receptor-targeted diphtheria toxin (DT-EGF)-induced
autophagic cell death [65]. In contrast, suppression of ATG5, ATG7, or ATG12 expression by
RNA interference (RNAi) inhibits autophagy and subsequent HMGB1 release after treatment
with DT-EGF in cancer cells [65]. In addition, ATG5-dependent autophagy promotes HMGB1
secretion in fibroblasts and macrophages after treatment with Hank’s balanced salt solution
and lipopolysaccharide [97, 133]. Antioxidant (e.g., N-acetyl-L-cysteine) inhibits the cytosolic
translocation and release of HMGB1 in starvation-induced autophagy [97]. In contrast, ROS
and knockdown of superoxide dismutases (SOD)-1 and SOD2 by RNAi promotes cytosolic
HMGB1 expression and extracellular release [134]. These findings suggest that oxidative stress
is involved in autophagy-mediated HMGB1 release.
4.2. Mechanism of HMGB1 release in apoptosis
An early study indicated that HMGB1 is released only by necrotic cells, but not apoptotic cells
[68]. However, recent studies demonstrated that activation of caspases and deoxyribonuclease
(DNase) in apoptosis regulates HMGB1 release and activity in apoptosis. Caspase-3 and
caspase-7 are important executioner caspases in apoptosis through amplified initiation signals
from caspase-8 and caspase-9. Activation of caspase-3 and -7 induces mitochondrial complex
1 protein p75 NDUFS1 cleavage, which results in mitochondrial ROS production and subse‐
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quent HMGB1 release during apoptosis in DCs [135]. Interestingly, the activity of released
HMGB1 in apoptosis is impaired, which promotes immunological resistance due to its
oxidized form [135]. In addition to caspase-3 and -7, caspase-1 is responsible for HMGB1
cleavage and release in the response to pyroptosis in immune cells [72, 136, 137]. This cas‐
pase-1-mediated HMGB1 fragment can rescue apoptosis-induced immune tolerance in a
RAGE-dependent manner [137]. Thus, different caspases can determine HMGB1 release and
action in apoptosis and pyroptosis.
DNase is responsible for DNA fragmentation during cell death. Activation of DNA endonu‐
clease (DNase-gamma) contributes to the degradation of DNA into nucleosomal units in
apoptosis, whereas activation of DNase I and II facilitates degradation of DNA in necrosis
[138]. The release of HMGB1 in apoptosis is triggered by DNase-gamma-mediated nucleoso‐
mal DNA fragmentation [139, 140]. Thus, inhibition of DNase gamma activity by small
molecular compound DR396 can significantly diminish HMGB1 release in response to
apoptotic stimuli [139, 140].
4.3. Mechanism of HMGB1 release in necrosis
The nuclear enzyme PARP1, which catalyzes the synthesis of the biopolymer poly(ADP-
ribose), exhibits an essential role in the DNA damage response and genomic stability. How‐
ever, overactivation of PARP1 may deplete the stores of cellular NAD+, which results in ATP
depletion and subsequent necrosis [141]. In fact, HMGB1 release in necrosis is regulated by
PARP1. Genetic and pharmacologic inhibition of PARP1 inhibits alkylating DNA damage
agent-mediated necrosis as well as HMGB1 release [142]. In addition to necrosis, activation of
PARP1 also contributes to HMGB1 translocation and release in autophagy and inflammation
[106, 143]. Interestingly, loss of HMGB1 in tissue and cells accelerates DNA damage that results
in PARP1 overactivation [144]. These findings suggest interplay between HMGB1 and PARP1
in response to cell death.
The RIP3-mediated signaling pathway is responsible for HMGB1 release in necroptosis.
Upregulation of RIP3 expression in vitro triggers necroptosis, whereas suppression of RIP3
expression by RNAi in vitro or in vivo significantly inhibits inflammatory stimuli-induced
necroptosis. RIP3-deficient mice exhibit resistance to sepsis and donor kidney inflammatory
injury. This anti-inflammatory function of RIP3 is due partly to inhibition of HMGB1 and
release of other DAMPs [145]. Additionally, RIP3-mediated necroptosis also contributes to
dsRNA/poly (I:C)-induced HMGB1 release [146]. This process promotes retinal degeneration
and triggers an inflammatory response in the mouse retina [146]. In addition to RIP3, inter‐
feron-β promoter stimulator 1 (an adaptor molecule for RIG-I-like receptors) may be critical
for poly (I:C)-induced HMGB1 release in necroptosis in DCs.
Cysteine cathepsins are lysosomal proteases with housekeeping functions that also initiate a
specific cell death pathway termed lysosomal cell death. This type of cell death includes
morphological features of necrosis and apoptosis [147]. Cathepsin B, a critical lysosomal
cysteine protease, mediates HMGB1 release following L. pneumophila-induced lysosomal cell
death [148]. Mechanically, cathepsin B can translocate from the lysosome to the nucleus, where
it interacts with HMGB1 and inhibits its cytosolic translocation. In addition to lysosomal cell
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death, cathepsin B is also important for HMGB1 release during inflammasome activation [149,
150]. In contrast, cathepsin D may facilitate HMGB1 release in necroptosis in DCs. The function
of other cathepsins in the regulation of HMGB1 release remains unknown.
5. Concluding remarks
HMGB1 is a member of family containing the evolutionarily conserved HMG box domains.
The function of HMGB1 depends on its cellular location. Besides its functions in the nucleus
and cytosol, HMGB1 plays a critical role in extracellular signaling associated with multiple
biological processes. Both intracellular and extracellular HMGB1 are involved in the regulation
of types of cell death such as apoptosis, necrosis, and autophagy. Intracellular HMGB1
regulates cell death in both transactional-dependent or transactional-independent manners.
In many cases, HMGB1 is a negative regulator of apoptosis and necrosis, but a positive
regulator of autophagy. In addition, the release and activity of HMGB1 in cell death is context-
dependent, which may cause immunogenic cell death or tolerogenic cell death. Future studies
are needed to define the upstream and downstream signaling of HMGB1 in the regulation of
cell death; clarify the interplay and cooperative role of HMGB1 and other DAMPs in the cell-
death-associated microenvironment; and develop new therapeutic strategies for targeting
HMGB1 in cell-death-associated disorders.
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